Disease Overview：Right heart failure（RHF）
Right heart failure (RHF) is a clinical syndrome characterized by the inability of the right ventricle to pump blood effectively into the pulmonary circulation, leading to systemic venous congestion and reduced cardiac output. It commonly arises secondary to left heart failure, pulmonary hypertension, chronic lung disease (e.g., COPD), or intrinsic right ventricular pathology such as arrhythmogenic cardiomyopathy or congenital heart defects. Key manifestations include jugular venous distension, hepatomegaly, peripheral edema, ascites, and fatigue. Diagnosis relies on comprehensive evaluation—including echocardiography with Doppler assessment of tricuspid regurgitation velocity and right ventricular function, BNP/NT-proBNP testing, cardiac MRI for structural quantification, and right heart catheterization when indicated. Management focuses on treating underlying etiology, optimizing volume status with diuretics, addressing pulmonary vascular resistance, and in advanced cases, considering targeted pulmonary vasodilators or mechanical circulatory support.
China offers distinct advantages for RHF management: cardiovascular centers in Beijing, Shanghai, and Guangzhou house internationally trained specialists with extensive experience in complex heart failure phenotypes, including isolated RHF. Advanced imaging—3T cardiac MRI, 4D flow echocardiography, and AI-enhanced hemodynamic modeling—is widely available and integrated into routine care. Clinical outcomes reflect this capability: multi-center registries report 1-year survival exceeding 82% in optimized RHF cohorts, with growing adoption of novel therapies like riociguat and selexipag under strict pharmacovigilance protocols. Cost-effectiveness is notable—comprehensive diagnostic workup and guideline-directed medical therapy cost approximately 40–60% less than equivalent care in the US or Western Europe, without compromising evidence-based standards.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: verifying hospital accreditation (JCI or CNAS-certified), coordinating appointments with designated heart failure teams, providing itemized, transparent pricing in advance, arranging visa support, medical translation, and post-discharge follow-up—all within a single, accountable service framework.
Right heart failure: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown for Right Heart Failure (Cardiovascular Department)
Non-Surgical / Conservative Management
*Target criteria:* NYHA Class I–III, stable hemodynamics, no acute decompensation, preserved renal/hepatic function.
- •Core Medications (Monthly, USD):
- Vasodilators (Sildenafil 20 mg TID): $45–$65 - Beta-blockers (Carvedilol titrated to 25 mg BID): $15–$22 - Anticoagulants (Rivaroxaban 10 mg/day if PE/AF present): $32–$48
- •Essential Monitoring (Per Episode, USD):
- Liver/kidney function panel + electrolytes: $22 - Transthoracic echocardiogram (TTE) with RV assessment: $75–$95 - 6-minute walk test + pulse oximetry: $18 - Chest X-ray (PA/lateral): $12
Surgical / Procedural / Interventional Options
*Eligibility:* NYHA Class III–IV despite ≥3 months optimized medical therapy; RVEF <35%; confirmed etiology (e.g., severe pulmonary hypertension, chronic thromboembolic disease, or corrected left-sided HF).
- •Preoperative Workup (One-time, USD):
- CT pulmonary angiography (CTPA): $185 - Cardiac MRI (RV volumetrics, strain analysis): $390 - Pulmonary function tests + V/Q scan: $110
- •Procedures (USD, inclusive of OR, anesthesia, 1-day ICU, and post-op monitoring):
- Pulmonary endarterectomy (PEA, single-stage): $18,500–$22,000 - Implantable pulmonary artery pressure sensor (CardioMEMS™): $12,800 - Heart-lung transplantation evaluation & listing (non-surgical phase): $3,200
Special / Complex Condition Management
- •Acute decompensated right HF with multiorgan failure:
- •Right HF secondary to congenital heart disease (e.g., Eisenmenger):
- •Refractory RV failure post-left ventricular assist device (LVAD):
Quick Selection Guide
- •Age <55, isolated CTEPH, budget >$20K: PEA offers curative potential — optimal first-line surgical choice.
- •Age 60–75, idiopathic PAH, moderate budget ($8K–$15K): BPA + Sildenafil/Riociguat — best risk-benefit balance.
- •Age >75, comorbid COPD/diabetes, NYHA III, budget <$3K/year: Optimized diuretics + Sildenafil + quarterly TTE — safest conservative pathway.
- •Acute RV shock, multiorgan failure: ICU-based inotrope support (Milrinone + Epinephrine) — immediate life-saving priority before definitive intervention.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Right heart failure Medical Vacation Packages
Curated transparent all-inclusive packages combining Right heart failure treatment with China top medical destinations:
